A Phase 4 interventional study of PK-model to decide when to dose Vedolizumab and Ustekinumab in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by Odense University Hospital. Enrolling by invitation at 6 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Odense University Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Inflammatory Bowel Diseases with a site in Denmark — 7 open to participants now, 10 under way, 1 of them phase 3. Inflammatory Bowel Diseases · Denmark.
Among the 65 studies in Inflammatory Bowel Diseases with a site in Denmark, this one is the 13th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 4, and was the 61st registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →7 of the 65 studies in Inflammatory Bowel Diseases with a site in Denmark are open now. Recruiting first, the newest first:
Nordsjaellands Hospital · Sites in Denmark
Ages 18+
Eli Lilly and Company · Sites in Denmark, United States, Canada and 4 more countries
Ages 3 wk+ · Women only
Esbjerg Hospital - University Hospital of Southern Denmark · Sites in Denmark, Sweden
Ages 18–40
Claus Anders Bertelsen, PhD, MD · Sites in Denmark
Ages 18+
University of Copenhagen · Sites in Denmark
Ages 18+ · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 13 · Phase 4 6
First in 2006; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 166 is above the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 111 across the 38 interventional studies, 80 across the 27 observational. Of the 46 that completed or were terminated, 11 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 65 have an industry lead sponsor. The 10 most frequent:
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
Odense University Hospital has 3 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Inflammatory Bowel Diseases with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06882993Esbjerg Hospital - University Hospital of Southern DenmarkFeasibility of a Minimally Invasive Diagnostic Algorithm in Suspected Crohn's Disease | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 65 studies in Inflammatory Bowel Diseases with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate if dosage of Ustekinumab (UST) and Vedolizumab (VDZ) based on Model-Informed Precision Dosing (MIPD) is equally as efficient in keeping adults with Inflammatory Bowel Disease (IBD) in remission as management based on what the treating physician deems best. The main question is:
Is using pharmacokinetic-pharmacodynamic (PK-PD) models to predict the appropriate dose and dosing interval for VDZ and UST at least as effective as current practices in maintaining IBD remission.
As above mentioned the comparison-group is adults with IBD, treated with UST or VDZ, managed as the physician deems best.
Participants will:
Have blood and stool tests done, as well as answer a questionnaire 4th weekly Have their dosage frequency decided on either by the PK-model or as the physician deems best visit the clinic once every 24 weeks for checkups. Have an endoscopy done at completion of the study (if the disease is primarily located in the small intestine, MRI or capsule endoscopy will be used instead)
Patients will 4th weekly have their drug-concentration in blood measured (and if low, also antidrug antibodies). Hemoglobin, Albumin, CRP and white blood cell count will also be done, as well as a stool-sample for calprotectin measurement.
For the control group however, the clinicians and patients will be blinded for the results of the blood- and stool samples, and the samples for drug concentration will not get analyzed before end of study.
4th weekly they will also answer PRO2 questionnaire, as well as the VAS-F. 8th weekly they will in addition to above mentioned also answer the EQ-5D-5L questionnaire.
At inclusion, after 24 weeks, and at 48 weeks the patients will in addition to the above mentioned also answer the short IBDQ and WPAI questionnaires, as well as be seen in the outpatient clinic to obtain HBI or SCCAI score as applicable, as well as to document any changes in concomitant medication or diseases, and to register if any serious adverse events have presented.
At completion of the trial, patients will have a endoscopy done.
In one subprotocol, the investigators will include 20 patients from Odense to have an endoscopy at both inclusion and completion. Here they will also have biopsies taken from all segments of the colon, which will be stores in a biobank for future research.
In another subprotocol 20 patients will be included to have a intestinal ultrasound done at inclusion and completion.
In a biobank for future research the investigators will also store serum-samples, buffy coat, and stool samples collected at inclusion, after 24 and 48 weeks from all included patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will have blood- and stool samples collected, as well as date and time of drug administration every 4th week. All of these informations, in addition to some informations collected at inclusion, will be used in a PK-model to prescribe when the next dosage of drug should be administered to keep the patient in the therapeutic window.
Drug: PK-model to decide when to dose Vedolizumab and Ustekinumab
Patients will have blood- and stool samples collected every 4 weeks, but these will be blinded for the physicians. They are to be treated as regular patients, but will be seen every 24 weeks to collect clinical activity scores, register alterations in concomitant medication and possible serious adverse events.
the pharmacokinetic model will include information about inflammatory parameters both in blood- and fecal samples, as well as weight, sex, previous treatments and drug concentration.
The fraction of patients in steroid-free remission
((for CD defined by PRO2 ≤ 4, for UC defined by PRO2 = 0) AND a fecal calprotectin ≤200)
Time frame: at the end of the observation period (48 weeks)
The fraction of the observation period (48 weeks) where the disease is in steroid-free remission
for CD defined by patient reported outcome 2 (PRO2) stool frequency \<= 3 and abdominal pain \< = 1, for UC defined by PRO2, number of abnormal stools for the patient, bleeding from the rectum = 0) AND a fecal calprotectin ≤ 200.
Time frame: this is registered every 4th week throughout the study duration of 48 weeks.
The financial costs associated with the two treatment strategies over the observation period (12 months)
expenditure on medicines (both expenditure on the purchase of medicines and expenditure on the administration of medicines), expenses for doctor visits / visits to a nurse, possibly expenses for hospitalization, possibly expenses for surgery, possibly expenses for sick leave and possibly expenses for early retirement. After end of study, the investigators will collect data on sick leave etc. from the national patient registry.
Time frame: through study completion, an average of 48 weeks
Endoscopic healing of the mucosa
for CD assessed by Simple Endoscopic Score for Crohn's Disease (SES-CD) \<3; and for UC assessed on the basis of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)≤1. If disease is primarily located in the small intestine, MRI or capsule endoscopy will be used instead, and assessed by the simplified MaRIA score \<1 or Lewis score ≤135, respectively
Time frame: at completion of study, approximately 48 weeks
Changes in quality of life during the study period
assessed by Short Inflammatory Bowel Disease Questionnaire (SIBDQ) difference between baseline and end of study. Improvement of quality of life indicated by a positive change of the SIBDQ. SIBDQ is collected at inclusion, week 24 and week 48. A higher the score, indicates a better outcome, Maksimum score of 70 points.
Time frame: 48 weeks
Quality of life as QALYs
assessed by the EuroQol-5 dimensions-5 levels questionnaire (EQ-5D-5L) and converted to QALYs. The cost per QALY will also be calculated. EQ-5D-5L is collected every 8th week throughout the study. Score ranges from 5-25, a higher score indicating poorer quality of life.
Time frame: 48 weeks
Clinical Disease Activity
assessed by Simplified Clinical Colitis Activity Index (SCCAI) for UC and Harvey-Bradshaw Index (HBI) for CD. These are collected at inclusion and every 24th week thereafter. SCCAI score ranges from 0-19, a higher score indicating a more severe disease activity. HBI score ranges from 0-20, a higher score indicating more severe disease activity.
Time frame: 48 weeks
Inflammatory burden over the observational period
CRP, albumin, hemoglobin, leukocyte counts and fecal calprotectin. These will be collected every 4th week
Time frame: 48 weeks
Expenses for analysis of drug concentration
patients will have drug concentrations analyzed every 4th week, the price of this will be collected
Time frame: 48 weeks
Expenses for drugs
patients will typically administer sc VDZ every 4th to 2nd week, iv VDZ every 12th to 4th week and UST every 12th to 4th week
Time frame: 48 weeks
Drug persistency
number of patients switching to another treatment during the study
Time frame: 48 weeks
Disease flares
assessed by consumption of glucocorticoids or IBD-related surgery
Time frame: 48 weeks
Fatigue
to assess if treating according to a PK-model results in less fatigue measured by Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F). Patients are asked to register how fatigued they feel every 4th week throughout the study. The VAS-F is a visual analogue scale that goes from 0-10, 10 indicating severe fatigue.
Time frame: 48 weeks.
Disease impact on work productivity and performance of daily activities
Assessed by difference in Work Productivity and Activity Impairment questionnaire (WPAI) scores and changes in scores between patients in the intervention- and control group. WPAI is collected at inclusion and every 24th week throughout the study. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Time frame: 48 weeks
Plan to share: Yes — De-identified individual participant data will possibly be shared, including clinical characteristics, laboratory test results, and patient-reported outcomes relevant to the study endpoints. Data will be available after publication of the main trial results and completion of any relevant follow-up studies. This is expected to occur approximately one year after the study's primary completion date. Data will be available for a minimum of 5 years following the publication of the trial results.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: will become available approximately March 2028 and will be available for at least 5 years
Access criteria: Data will be shared with qualified researchers conducting legitimate scientific inquiries, particularly those working within the field of inflammatory bowel disease (IBD) and therapeutic drug monitoring (TDM)
Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.
Of 33 non-industry phase 4 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 63. This study's planned 23 months is below that.
Counting every sponsor, half of 38 studies reached it within 38 months; a quarter within 21 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Sep 2025 → Jan 2026, primary completion Aug 2027 → Dec 2027 and completion Nov 2027 → Nov 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.